Guoyao Holdings is a core enterprise of China National Pharmaceutical Group Co., Ltd. (ranked 199th in the Fortune Global 500), established in January 2003 and listed on the Hong Kong Stock Exchange in September 2009 (01099. HK). Since its establishment more than ten years ago, the business scale has continuously expanded, the quality of operation has continuously improved, and the profitability has continued to grow. It has now developed into a leading distributor and retailer of drugs and healthcare products in China, as well as a leading supply chain service provider. It has formed an integrated industrial chain for the coordinated development of multiple formats in the pharmaceutical and health field, including product distribution and distribution, retail diagnosis and treatment, chemical reagents, medical devices, and medical and health services. Since 2005, it has consistently ranked first in sales among Chinese pharmaceutical commercial enterprises. In 2011, it was awarded the title of the first domestic pharmaceutical circulation business enterprise with a revenue of over 100 billion yuan. In 2016, the company achieved a revenue of 258.388 billion yuan, with sales growth consistently leading the industry average. Profit growth significantly exceeded sales growth for three consecutive years, and the expense ratio was the lowest in history since its listing. In 2017, it ranked 22nd on the Fortune China 500 list. As of June 2017, the company had a registered capital of 2.767 billion yuan, total assets of 173.504 billion yuan, and 56000 employees.

Sinopharm Holdings currently has 480 subsidiaries (including two listed companies, Sinopharm Corporation and Sinopharm Tongyi), with a drug distribution and delivery network covering 31 provinces (cities, districts) across the country, including 214 cities out of 335 prefecture level and above cities. It has established four hub level logistics centers in Beijing, Shanghai, Xi'an, and Guangzhou, 38 provincial-level logistics centers, 24 retail centers, and 185 prefecture level logistics centers, creating a "smart logistics"+"cold chain brand" and providing smart pharmaceutical supply chain services to 214000 customers and well-known enterprises.

Sinopharm Holdings is vigorously developing its retail diagnosis and treatment business around the core strategy of "integration of wholesale and retail". The affiliated "Guoyao Holdings Guoda Pharmacy Co., Ltd." is the top revenue pharmaceutical retail operator in China. Belonging to "Guoyao Health Online Co., Ltd.", it ranks first in comprehensive online drug sales in China (2016) and has completed Series A financing of 120 million yuan. A pharmaceutical retail chain network has been formed, with parallel online and offline channels and stores located in major cities across the country. At present, there are 4106 retail pharmacies, including 3693 large pharmacies in China, and 413 retail pharmacies operated by various distribution companies. The company actively builds its second retail brand SPS+professional pharmacy, and has currently opened more than 30 stores.

China National Pharmaceutical Group's subsidiary, "China National Pharmaceutical Group Medical Equipment Co., Ltd.", is a medical device integrated service operator that integrates product cooperation research and development, sales agency, logistics distribution, and after-sales service. Focusing on overall hospital services, integrating multiple business models, providing customers with one-stop integrated solutions and diversified value-added services, committed to building a medical device supply chain integrated service platform.

China National Pharmaceutical Group Chemical Reagent Co., Ltd., a subsidiary of China National Pharmaceutical Group Corporation, is the first professional company in China to operate chemical reagents and glassware. It is a professional manufacturer and distributor of large-scale chemical reagents, experimental consumables, instrument equipment, experimental furniture and other products in China. Its product applications cover biotechnology, environmental testing, drug research and development, educational experiments and other fields; Having Shanghai famous trademarks such as "Shanghai Test" and "Wokai", as well as Shanghai famous brand products.

Guoyao Holdings (China) Financial Leasing Co., Ltd., a subsidiary of Guoyao Holdings, relies on financial leasing business as its core and also engages in integrated business such as commercial factoring and investment, providing customers with investment consulting, financial consulting, management consulting PPP、 Comprehensive financial services such as asset management. Fully layout the medical and health industry, covering all aspects of the medical and health industry chain, including production, circulation, retail, and medical terminals.

Sinopharm Holdings has long undertaken the task of national medicine reserve and emergency supply. At critical moments such as the "SARS" in 2003, the severe snow disaster and Wenchuan earthquake in the south in 2008, the Yushu earthquake in 2010, the Ya'an earthquake in 2013, the devastating flood in Wuhan in 2016, and the Jiuzhaigou Valley Scenic and Historic Interest Area earthquake in 2017, Sinopharm Holdings fulfilled national orders, shouldered social responsibilities, resolutely completed the allocation and distribution of reserved drugs, and played an important role in ensuring people's life safety and social stability.

In the face of the new trend of the global pharmaceutical economy, Sinopharm Holdings will stand at a new historical starting point, take the opportunity of deepening the reform of mixed ownership, take innovation driven as the engine, through scientific and technological innovation, apply Internet technology, focus on the core strategy of "wholesale and retail integration", vigorously carry out innovative value-added businesses such as equipment, cold chain, hospital medical services, diagnosis and treatment, medical e-commerce, financial services, health management, constantly promote the transformation of the company from a traditional service-oriented enterprise to a technology-based service enterprise, build a "smart medical service ecosystem", become an outstanding global medical health service provider, and continue to create greater value for human health and a better life.